title: Thyromimetics: What does the future hold?
abstract: Thyromimetic agents that can treat dyslipidemia without adverse effects like cardiac arrhythmias and osteoporosis are attractive options. Initial experience with desssicated thyroid hormone extract and DT4 were disappointing. Thyroid hormone has nuclear action with four receptor isoforms- TR α1, TRα2, TRβ1, TRβ2. TR α1 has predominant effects on CVS, TRβ2 acts mainly on the pituitary and TRβ1 has hepatoselective action and decrease cholesterol levels. Eprotirome and Sobetirome are 2 thyromimetics that have selective TRβ1 activity. They act in dyslipidemia by multiple mechanisms. They are presumably safe on the pituitary- thyroid axis.
authors.affiliation: Department of Endocrinology, Amrita Institute of Medical Sciences, Cochin, Kerala, India.
authors.forename: A G
authors.initials: AG
authors.lastname: Unnikrishnan
authors.forename: Manash
authors.initials: M
authors.lastname: Baruah
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
keywords: Thyromimetics; dyslipidemia
references.citation: World J Gastroenterol. 2010 Dec 21;16(47):5958-64
references.pmid: 21157972
references.citation: J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):31-42
references.pmid: 11384861
references.citation: Curr Opin Lipidol. 2010 Dec;21(6):499-506
references.pmid: 20935564
references.citation: Arch Intern Med. 1995 Jul 24;155(14):1490-5
references.pmid: 7605150
references.citation: Mol Endocrinol. 1990 May;4(5):743-8
references.pmid: 2274056
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10297-302
references.pmid: 16006512
references.citation: J Med Chem. 2012 Jun 28;55(12):5649-75
references.pmid: 22512468
references.citation: N Engl J Med. 2010 Mar 11;362(10):906-16
references.pmid: 20220185
references.citation: Curr Opin Investig Drugs. 2009 Sep;10(9):912-8
references.pmid: 19705333